Company registration number 07208355 (England and Wales)
IBEX INNOVATIONS LTD
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026
PAGES FOR FILING WITH REGISTRAR
IBEX INNOVATIONS LTD
CONTENTS
Page
Statement of financial position
1
Statement of changes in equity
2
Notes to the financial statements
3 - 9
IBEX INNOVATIONS LTD
STATEMENT OF FINANCIAL POSITION
AS AT
31 MARCH 2026
31 March 2026
- 1 -
2026
2025
Notes
£
£
£
£
Fixed assets
Tangible assets
3
14,046
21,590
Current assets
Debtors
4
349,884
386,066
Cash at bank and in hand
654,412
1,700,268
1,004,296
2,086,334
Creditors: amounts falling due within one year
5
(117,646)
(348,504)
Net current assets
886,650
1,737,830
Net assets
900,696
1,759,420
Capital and reserves
Called up share capital
76
75
Share premium account
3,394,475
3,244,476
Other reserves
506,606
172,055
Profit and loss reserves
(3,000,461)
(1,657,186)
Total equity
900,696
1,759,420

The directors of the company have elected not to include a copy of the income statement within the financial statements.true

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 26 August 2026 and are signed on its behalf by:
Dr P D Scott
Director
Company Registration No. 07208355
IBEX INNOVATIONS LTD
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2026
- 2 -
Share capital
Share premium account
Equity reserve
Share options reserve
Profit and loss reserves
Total
Notes
£
£
£
£
£
£
Balance at 1 April 2024
51
3,489,595
11,043
128,693
(3,951,948)
(322,566)
Year ended 31 March 2025:
Loss and total comprehensive income for the year
-
-
-
-
(1,256,991)
(1,256,991)
Issue of share capital
24
3,244,476
-
-
-
3,244,500
Issue of convertible loan
-
-
(11,043)
-
-
(11,043)
Credit to equity for equity settled share-based payments
-
-
-
-
62,158
62,158
Reduction of shares
-
0
(3,489,595)
-
-
3,489,595
-
0
Charge in the year
-
-
-
43,362
-
43,362
Balance at 31 March 2025
75
3,244,476
-
0
172,055
(1,657,186)
1,759,420
Year ended 31 March 2026:
Loss and total comprehensive income for the year
-
-
-
-
(1,343,275)
(1,343,275)
Issue of share capital
1
149,999
-
-
-
150,000
Charge in the year
-
-
-
334,551
-
334,551
Balance at 31 March 2026
76
3,394,475
-
0
506,606
(3,000,461)
900,696
IBEX INNOVATIONS LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026
- 3 -
1
Accounting policies
Company information

IBEX Innovations Ltd is a private company limited by shares incorporated in England and Wales. The registered office is Netpark Plexus, Thomas Wright Way, Sedgefield, County Durham, United Kingdom, TS21 3FD.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2
Going concern

The company meets its day to day working capital requirements through cash generated from operations and mainly grant funding and equity investment. The business has made strong commercial progress over the last 12 months which has set the foundations to exceed the modest sales forecast for 2026/27 and the business is now positioned as an excellent investment opportunity with the business poised to grow substantially over the next 10 years. IBEX now has a product that can be sold to hospitals in the UK and Europe and this is being promoted by commercial partners.

 

At the year end the company reported net assets of £900,696 and cash balances of £654,412. The directors have prepared cash flows for the next 12 months which show that the company should have sufficient available funds to allow it to continue in operation for that period. The cash flow forecasts assume a successful completion of a funding round to raise additional working capital for the business which has not yet been completed. Draft terms have not yet been agreed with investors; however, the directors are confident that the funding round will successfully complete. At the time of signing the financial statements, this is not legally complete and so represents a material uncertainty which may cast significant doubt over the company's ability to continue as a going concern.

 

The directors have prepared a contingency operating plan involving operational restructuring and cost reductions. This plan ensures that existing operating capital is sufficient to cover the company's liabilities for at least the next 12 months without a fundraise, while focusing resources on servicing existing customers and scaling back non-essential development activities.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods and intellectual property is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods or the transfer of right of use of IP), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably.

IBEX INNOVATIONS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
1
Accounting policies
(Continued)
- 4 -
1.4
Research and development expenditure

Research and development expenditure is written off against profits in the year in which it is incurred.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and machinery
25% reducing balance
Fixtures and fittings
25% reducing balance
Office Equipment
33% straight line
Software
25% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand.

1.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

IBEX INNOVATIONS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
1
Accounting policies
(Continued)
- 5 -
Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.9
Equity instruments

Ordinary shares are classed as equity. Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.10
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

IBEX INNOVATIONS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
1
Accounting policies
(Continued)
- 6 -
1.11
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.13
Share-based payments

Equity-settled share-based payments are measured at fair value at the date of grant by reference to the fair value of the equity instruments granted. The fair value determined at the grant date is expensed on a straight-line basis over the vesting period, based on the estimate of shares that will eventually vest. A corresponding adjustment is made to equity.

When the terms and conditions of equity-settled share-based payments at the time they were granted are subsequently modified, the fair value of the share-based payment under the original terms and conditions and under the modified terms and conditions are both determined at the date of the modification. Any excess of the modified fair value over the original fair value is recognised over the remaining vesting period in addition to the grant date fair value of the original share-based payment. The share-based payment expense is not adjusted if the modified fair value is less than the original fair value.

 

Cancellations or settlements (including those resulting from employee redundancies) are treated as an acceleration of vesting and the amount that would have been recognised over the remaining vesting period is recognised immediately.

1.14
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

1.15
Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

 

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

1.16
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

IBEX INNOVATIONS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
- 7 -
2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2026
2025
Number
Number
Total
19
20
3
Tangible fixed assets
Plant and machinery
Fixtures and fittings
Office Equipment
Software
Total
£
£
£
£
£
Cost
At 1 April 2025
33,936
4,238
117,918
28,902
184,994
Additions
-
0
-
0
600
-
0
600
Disposals
-
0
-
0
(482)
-
0
(482)
At 31 March 2026
33,936
4,238
118,036
28,902
185,112
Depreciation and impairment
At 1 April 2025
18,655
3,397
112,450
28,902
163,404
Depreciation charged in the year
3,820
210
4,114
-
0
8,144
Eliminated in respect of disposals
-
0
-
0
(482)
-
0
(482)
At 31 March 2026
22,475
3,607
116,082
28,902
171,066
Carrying amount
At 31 March 2026
11,461
631
1,954
-
0
14,046
At 31 March 2025
15,281
841
5,468
-
0
21,590
4
Debtors
2026
2025
Amounts falling due within one year:
£
£
Trade debtors
87,199
-
0
Corporation tax recoverable
245,044
246,746
Other debtors
-
0
1,323
Prepayments and accrued income
17,641
137,997
349,884
386,066
IBEX INNOVATIONS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
- 8 -
5
Creditors: amounts falling due within one year
2026
2025
£
£
Trade creditors
11,348
243,755
Taxation and social security
43,440
22,795
Other creditors
14,528
19,262
Accruals and deferred income
48,330
62,692
117,646
348,504
6
Share Options

Share options

The company has a share option scheme for employees to enable them to acquire ordinary shares of £0.00001 each in the capital of the company. The options vest over a period of 3 years and lapse the earlier of 10 years after the date of issue and the employee leaving the company. Options may be exercised once the vesting period is completed and have no performance conditions attached. Options may also be exercised on the occurrence of an exit event. Exit events include:

 

(a) a listing on the London Stock Exchange, the Alternative Investment Market or any other Recognised Investment Exchange;

 

(b) a sale; or

 

(c) any other event which the Board, in its absolute discretion considers to be an exit event.

 

The fair value of the options at grant date issued in the year ended 31 March 2026 are based on a share price of £1.47 following a share issue at that price during the year.

 

The opening number of share options available for issue was 550,949. There have been 495,475 share options issued in the year and no options have been exercised or cancelled. The closing number of shares available for issue is 55,474.

 

The company has taken advantage of the provisions of FRS 102 Section 1A to not recognise any share options charge on options granted before 1 April 2016. The charge to the Income Statement for the year ended 31 March 2026 is £334,551 (2025 - £43,362).

7
Financial commitments, guarantees and contingent liabilities

Amounts disclosed in the statement of financial position

 

Included in the statement of financial position are unpaid pension contributions of £13,385 (2025 - £16,115).

8
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2026
2025
£
£
2,302
8,657
IBEX INNOVATIONS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
- 9 -
9
Related party transactions
Transactions with related parties

During the year the company entered into the following transactions with related parties:

Convertible loan note transactions
Interest paid on convertible loan note
2026
2025
2026
2025
£
£
£
£
Directors
-
1,419,500
-
122,278

There were no convertible loan note transactions in the year.

 

 

Purchase of Shares By Related Party

 

During the year, the company issued 102,041 ordinary shares to a related party for consideration of £150,000, which was received in full during the year. The shares were issued at a share price of £1.47. The related party is North East Finance - an existing shareholder of Ibex Innovations Limited.

 

 

10
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006:

The auditor's report was unqualified.

Material uncertainty relating to going concern

The company incurred a loss before tax of £1,586,360 during the year ended 31 March 2026. As of that date, the company had negative profit and loss reserves of £3,000,461 which were offset against other reserves to show positive net assets of £900,696. These events or conditions, along with other matters as set forth in Note 1.2, indicate that a material uncertainty exists that may cast significant doubt on the company’s ability to continue as a going concern.

 

Our opinion is not modified in respect of this matter.

Senior Statutory Auditor:
Angela Ingham FCA
Statutory Auditor:
Azets Audit Services
2026-03-312025-04-01falsefalsefalse01 September 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityDr N LoxleyMr A D MitchellMr B PeecockDr P D ScottIP2IPO Services LimitedMr S A Gall072083552025-04-012026-03-31072083552026-03-31072083552025-03-3107208355core:PlantMachinery2026-03-3107208355core:FurnitureFittings2026-03-3107208355core:ComputerEquipment2026-03-3107208355core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2026-03-3107208355core:PlantMachinery2025-03-3107208355core:FurnitureFittings2025-03-3107208355core:ComputerEquipment2025-03-3107208355core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2025-03-3107208355core:CurrentFinancialInstrumentscore:WithinOneYear2026-03-3107208355core:CurrentFinancialInstrumentscore:WithinOneYear2025-03-3107208355core:ShareCapital2026-03-3107208355core:ShareCapital2025-03-3107208355core:SharePremium2026-03-3107208355core:SharePremium2025-03-3107208355core:OtherMiscellaneousReserve2026-03-3107208355core:OtherMiscellaneousReserve2025-03-3107208355core:RetainedEarningsAccumulatedLosses2026-03-3107208355core:RetainedEarningsAccumulatedLosses2025-03-3107208355core:ShareCapital2024-03-3107208355core:SharePremium2024-03-3107208355core:OtherReservesSubtotal2024-03-3107208355core:RetainedEarningsAccumulatedLosses2024-03-3107208355core:OtherReservesSubtotal2025-03-3107208355core:OtherReservesSubtotal2026-03-3107208355bus:Director42025-04-012026-03-3107208355core:RetainedEarningsAccumulatedLosses2024-04-012025-03-31072083552024-04-012025-03-3107208355core:RetainedEarningsAccumulatedLosses2025-04-012026-03-3107208355core:ShareCapital2024-04-012025-03-3107208355core:SharePremium2024-04-012025-03-3107208355core:ShareCapital2025-04-012026-03-3107208355core:SharePremium2025-04-012026-03-3107208355core:OtherReservesSubtotal2024-04-012025-03-3107208355core:PlantMachinery2025-04-012026-03-3107208355core:FurnitureFittings2025-04-012026-03-3107208355core:ComputerEquipment2025-04-012026-03-3107208355core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2025-04-012026-03-3107208355core:PlantMachinery2025-03-3107208355core:FurnitureFittings2025-03-3107208355core:ComputerEquipment2025-03-3107208355core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2025-03-31072083552025-03-3107208355core:CurrentFinancialInstruments2026-03-3107208355core:CurrentFinancialInstruments2025-03-3107208355bus:PrivateLimitedCompanyLtd2025-04-012026-03-3107208355bus:SmallCompaniesRegimeForAccounts2025-04-012026-03-3107208355bus:FRS1022025-04-012026-03-3107208355bus:Audited2025-04-012026-03-3107208355bus:Director12025-04-012026-03-3107208355bus:Director22025-04-012026-03-3107208355bus:Director32025-04-012026-03-3107208355bus:Director52025-04-012026-03-3107208355bus:Director62025-04-012026-03-3107208355bus:FullAccounts2025-04-012026-03-31xbrli:purexbrli:sharesiso4217:GBP